Detalles de la búsqueda
1.
Open-label investigation of rapid initiation of extended-release buprenorphine in patients using fentanyl and fentanyl analogs.
Am J Addict
; 33(1): 8-14, 2024 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-37936553
2.
Open-label, rapid initiation pilot study for extended-release buprenorphine subcutaneous injection.
Am J Drug Alcohol Abuse
; 49(1): 43-52, 2023 01 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-36001871
3.
Effect of ileal bile acid transporter inhibitor GSK2330672 on pruritus in primary biliary cholangitis: a double-blind, randomised, placebo-controlled, crossover, phase 2a study.
Lancet
; 389(10074): 1114-1123, 2017 03 18.
Artículo
en Inglés
| MEDLINE | ID: mdl-28187915
4.
BAT117213: Ileal bile acid transporter (IBAT) inhibition as a treatment for pruritus in primary biliary cirrhosis: study protocol for a randomised controlled trial.
BMC Gastroenterol
; 16(1): 71, 2016 Jul 19.
Artículo
en Inglés
| MEDLINE | ID: mdl-27431238
5.
Selective sodium-dependent glucose transporter 1 inhibitors block glucose absorption and impair glucose-dependent insulinotropic peptide release.
Am J Physiol Gastrointest Liver Physiol
; 308(11): G946-54, 2015 Jun 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-25767259
6.
Pharmacokinetics and Pharmacodynamics of the SGLT2 Inhibitor Remogliflozin Etabonate in Subjects with Mild and Moderate Renal Impairment.
Drug Metab Dispos
; 43(7): 1077-83, 2015 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-25934577
7.
Assessment of the drug interaction risk for remogliflozin etabonate, a sodium-dependent glucose cotransporter-2 inhibitor: evidence from in vitro, human mass balance, and ketoconazole interaction studies.
Drug Metab Dispos
; 40(11): 2090-101, 2012 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-22851617
8.
Modeling buprenorphine reduction of fentanyl-induced respiratory depression.
JCI Insight
; 7(9)2022 05 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-35316224
9.
Tolerance to Opioid-Induced Respiratory Depression in Chronic High-Dose Opioid Users: A Model-Based Comparison With Opioid-Naïve Individuals.
Clin Pharmacol Ther
; 109(3): 637-645, 2021 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-32865832
10.
Pharmacodynamics, pharmacokinetics, safety, and tolerability of albiglutide, a long-acting glucagon-like peptide-1 mimetic, in patients with type 2 diabetes.
J Clin Endocrinol Metab
; 93(12): 4810-7, 2008 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-18812476
11.
MRI assessment of drug-induced fluid accumulation in humans: validation of the technology.
Magn Reson Imaging
; 26(5): 629-37, 2008 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-18420368
12.
Increased cardiovascular risk associated with diabetes in Dallas County.
Am Heart J
; 151(5): 1087-93, 2006 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-16644340
13.
The composition of dietary fat directly influences glucose-stimulated insulin secretion in rats.
Diabetes
; 51(6): 1825-33, 2002 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-12031970
14.
Knockout mice lacking steroidogenic factor 1 are a novel genetic model of hypothalamic obesity.
Endocrinology
; 143(2): 607-14, 2002 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-11796516
15.
Effect of glucose-insulin-potassium infusion on plasma free fatty acid concentrations in patients undergoing primary percutaneous coronary intervention for ST-elevation myocardial infarction.
Am J Cardiol
; 94(10): 1288-9, 2004 Nov 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-15541248
16.
Exploring glycosuria as a mechanism for weight and fat mass reduction. A pilot study with remogliflozin etabonate and sergliflozin etabonate in healthy obese subjects.
J Clin Transl Endocrinol
; 1(1): e3-e8, 2014 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-29235586
17.
Safety, pharmacokinetics and pharmacodynamics of remogliflozin etabonate, a novel SGLT2 inhibitor, and metformin when co-administered in subjects with type 2 diabetes mellitus.
BMC Pharmacol Toxicol
; 14: 25, 2013 Apr 30.
Artículo
en Inglés
| MEDLINE | ID: mdl-23631443
18.
First human dose-escalation study with remogliflozin etabonate, a selective inhibitor of the sodium-glucose transporter 2 (SGLT2), in healthy subjects and in subjects with type 2 diabetes mellitus.
BMC Pharmacol Toxicol
; 14: 26, 2013 May 13.
Artículo
en Inglés
| MEDLINE | ID: mdl-23668634
19.
Discovery of a highly potent, nonabsorbable apical sodium-dependent bile acid transporter inhibitor (GSK2330672) for treatment of type 2 diabetes.
J Med Chem
; 56(12): 5094-114, 2013 Jun 27.
Artículo
en Inglés
| MEDLINE | ID: mdl-23678871
20.
Remogliflozin etabonate, a selective inhibitor of the sodium-glucose transporter 2, improves serum glucose profiles in type 1 diabetes.
Diabetes Care
; 35(11): 2198-200, 2012 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-23011728